This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, H.-L. C. Articles by Zajchowski, D. A. Search for Related Content PubMed PubMed Citation Articles by Liu, H.-L. C. Articles by Zajchowski, D. A.

The Novel Estrogen-Responsive B Box Protein (EBBP) Gene Is Tamoxifen Regulated in Cells Expressing an Estrogen Receptor DNA-Binding Domain Mutant

Departments of Cancer (H.L.L., L.W., D.A.Z.), Biophysics (M.H.S.), and Biologics Research (J.M.) Berlex Biosciences Richmond, California 94804

We have identified a 2.6-kb mRNA whose steady state levels are increased 2- to 4-fold by treatment of human mammary epithelial cells (HMEC) stably expressing an estrogen receptor (ER) transgene with either estrogen (E) or the antiestrogen, 4- hydroxy-tamoxifen (HT). The cDNA corresponding to this mRNA encodes a 564-amino acid protein, named estrogen-responsive B box protein (EBBP), that is a new member of a subfamily within the B box zinc finger protein family, which includes transcription factors (e.g. TIF1), tumor suppressor proteins (e.g. PML), and proteins implicated in development (e.g. ret finger protein, XNF7). The EBBP mRNA is detectable by Northern blot analysis in most tissues, with the exception of liver and peripheral blood lymphocytes, and the gene has been mapped to human chromosome 17p11.2. In contrast to most B box family members, EBBP has a predominantly cytoplasmic localization. Studies of the estrogenic regulation of EBBP expression demonstrated that the E-dependent increase in EBBP mRNA levels in the ER-transfected HMEC is an early, ER-mediated, and cycloheximide-insensitive process. In HMEC stably transfected with an ER mutant containing a deletion in the second zinc finger of the DNA-binding domain, E and HT had different effects on EBBP gene expression; EBBP regulation by E was dramatically reduced while the effects of HT were augmented. These data indicate that HT can modulate EBBP mRNA expression through a mutated ER, which has little activity when bound by E, and suggest that different molecular mechanisms control the E and HT responsiveness of the EBBP gene.

This article has been cited by other articles:

				E. L. Hsu, D. Yoon, H. H. Choi, F. Wang, R. T. Taylor, N. Chen, R. Zhang, and O. Hankinson A Proposed Mechanism for the Protective Effect of Dioxin against Breast Cancer Toxicol. Sci., August 1, 2007; 98(2): 436 - 444. [Abstract] [Full Text] [PDF]

				S. M Johnson, M. Maleki-Dizaji, J. A Styles, and I. N H White Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen Endocr. Relat. Cancer, June 1, 2007; 14(2): 337 - 350. [Abstract] [Full Text] [PDF]

				B. B. Cheung, J. Bell, A. Raif, A. Bohlken, J. Yan, B. Roediger, A. Poljak, S. Smith, M. Lee, W. D. Thomas, et al. The Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid Signal J. Biol. Chem., June 30, 2006; 281(26): 18246 - 18256. [Abstract] [Full Text] [PDF]

				M. Becker, A. Sommer, J. R. Kratzschmar, H. Seidel, H.-D. Pohlenz, and I. Fichtner Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM Mol. Cancer Ther., January 1, 2005; 4(1): 151 - 170. [Abstract] [Full Text] [PDF]

				H.-D. Beer, C. Munding, N. Dubois, C. Mamie, D. Hohl, and S. Werner The Estrogen-responsive B Box Protein. A NOVEL REGULATOR OF KERATINOCYTE DIFFERENTIATION J. Biol. Chem., May 31, 2002; 277(23): 20740 - 20749. [Abstract] [Full Text] [PDF]

				D. A. Zajchowski, M. F. Bartholdi, Y. Gong, L. Webster, H.-L. Liu, A. Munishkin, C. Beauheim, S. Harvey, S. P. Ethier, and P. H. Johnson Identification of Gene Expression Profiles That Predict the Aggressive Behavior of Breast Cancer Cells Cancer Res., July 1, 2001; 61(13): 5168 - 5178. [Abstract] [Full Text] [PDF]

				B. S. Shoker, C. Jarvis, R. B. Clarke, E. Anderson, J. Hewlett, M. P. A. Davies, D. R. Sibson, and J. P. Sloane Estrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous Breast Am. J. Pathol., December 1, 1999; 155(6): 1811 - 1815. [Abstract] [Full Text] [PDF]

				P. Webb, P. Nguyen, C. Valentine, G. N. Lopez, G. R. Kwok, E. McInerney, B. S. Katzenellenbogen, E. Enmark, J.-A. Gustafsson, S. Nilsson, et al. The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions Mol. Endocrinol., October 1, 1999; 13(10): 1672 - 1685. [Abstract] [Full Text]

				D. A. Zajchowski, K. Kauser, D. Zhu, L. Webster, S. Aberle, F. A. White III, H.-L. Liu, R. Humm, J. MacRobbie, P. Ponte, et al. Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints J. Biol. Chem., May 19, 2000; 275(21): 15885 - 15894. [Abstract] [Full Text] [PDF]